Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response.
体外研究(In Vitro)
Vopratelimab (JTX-2011; 0.001-10 μg/mL; 3 d; CD4 T 细胞) 具有激活原代人 T 细胞的活性,驱动 IFNγ、IL-17a、IL-10、IL-9、GM-CSF、TNFα 和 IL-21 分泌。 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; 每周两次,持续 2 周) 促进 Sa1/N 小鼠同基因肿瘤模型中的肿瘤消退。 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Female A/J, Balb/c and C57BL/6 mice with Sa1/N mur
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595.